Breaking News, Promotions & Moves

Byondis Names New CEO

Christoph Korpus, PhD, MBA, will guide the advancement of R&D activities for Byondis’ novel antibody-drug conjugate (ADC) technology platforms.

Author Image

By: Charlie Sternberg

Associate Editor

Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, has appointed Christoph Korpus, PhD, MBA, as Chief Executive Officer (CEO), effective immediately. Korpus has served as Chief Business Officer (CBO) of the Company since January 2025. He succeeds Byondis Founder and former CEO Jacques Lemmens, PhD, who will remain on the Board of Directors as Chairman. In his new role as CEO, Korpus will guide the advancement of research ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics